Back Login to subscribe 🔔 Set Alert

URGN UroGen Pharma Ltd. Ordinary Shares

15 min delay

Loading...

Loading...

Loading...

Loading options…

CALLS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

PUTS

Strike	Last	Bid	Ask	Mark	IV	Volume	OI	Δ Delta	Θ Theta

Loading insider data…

Date	Headline	Sentiment
	HC Wainwright & Co. Reiterates Buy on UroGen Pharma, Maintains $45 Price Target	89.93%
	UroGen Announces That UGN-103 Achieved A 94.5% Durability Of Response At Six Months In The Ongoing Phase 3 UTOPIA Trial For Intravesical Solution In Patients With Bladder Cancer	88.31%
	UroGen Pharma Announces 36-Month Duration Of Response By Kaplan-Meier Estimate In Patients Who Achieved Complete Response At Three Months In Pivotal Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution.	82.66%
	HC Wainwright & Co. Maintains Buy on UroGen Pharma, Raises Price Target to $45	76.49%
	Oppenheimer Maintains Outperform on UroGen Pharma, Raises Price Target to $40	91.99%
	Earnings Scheduled For May 6, 2026	69.37%
	UroGen Pharma Reports Q1 2026 Results: Full Earnings Call Transcript	81.03%
	UroGen To Host KOL Panel Highlighting Real-World Experience With ZUSDURI At AUA Annual Meeting On May 17	89.81%
	UroGen Pharma Q1 EPS $(0.47) Beats $(0.48) Estimate, Sales $50.959M Beat $44.820M Estimate	89.02%